MARLBOROUGH, Mass.--(BUSINESS WIRE)--

Advanced Cell Technology, Inc. (ACT; OTCBB: ACTC), a leader in the field of regenerative medicine, announced today that it has been issued a patent in Australia, patent number 2005325753, Improved modalities for the treatment of degenerative diseases of the retina. The patent broadly covers the use of human retinal pigment epithelial (RPE) cells generated from pluripotent stem cells in the manufacture of pharmaceutical preparations of RPE cells, and the use of those preparations to treat patients with degenerative diseases of the retina such as Age-related Macular Degeneration. The patent covers the pharmaceutical formulation of human RPE cells made from a range of pluripotent stem cells, including both human embryonic stem cells (hESCs) and human induced pluripotent stem (iPS) cells.

We continue to make great progress with our patent estate covering RPE therapies, said Gary Rabin, chairman and CEO of ACT. Our ongoing success in securing broad patent protection around the world, including this newly-issued Australian patent, is a testament to our innovative chief scientific officer, Dr. Robert Lanza, and the rest of our scientific team.

The efficient production of highly pure RPE cell preparations represents a critical step in the creation of renewable sources of transplantable cells that can be used to target degenerative diseases of the eye such as Stargardts Macular Dystrophy (SMD) and dry Age-related Macular Degeneration (dry AMD).

Our current embryonic stem cell trials pave the way for other pluripotent stem cell therapies, commented Dr. Lanza. ACTs cellular reprogramming technologies using iPS cells are in an advanced stage of development, and we hope to be in a position to move toward clinical translation in the not-too-distant future. Since iPS cells can be made from the patients own cells such as skin or blood cells they may allow us to expand our cell therapies beyond immune-privileged sites such as the eye without the risk of immune rejection.

Mr. Rabin concluded, We are aggressively pursuing patent protection for a variety of aspects of our programs. Our intellectual property strategy includes both vigilance in pursuing comprehensive coverage from our initial patent filings, such as this new Australian patent, and filing for protection around our scientific teams various innovations. At the same time we are paying close attention to including within our patent coverage those ways others may wish to adapt our technology for commercial use, such as through the choice of stem cell source, or the use of solid supports or cell suspensions for delivery. Following this strategy, we are establishing both formidable barriers-to-entry for potential competitors, as well as strong potential licensing opportunities for others, translating into solid revenue generation possibilities for the company.

About Advanced Cell Technology, Inc.

Advanced Cell Technology, Inc., is a biotechnology company applying cellular technology in the field of regenerative medicine. For more information, visit http://www.advancedcell.com.

Forward-Looking Statements

Statements in this news release regarding future financial and operating results, future growth in research and development programs, potential applications of our technology, opportunities for the company and any other statements about the future expectations, beliefs, goals, plans, or prospects expressed by management constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Any statements that are not statements of historical fact (including statements containing the words will, believes, plans, anticipates, expects, estimates, and similar expressions) should also be considered to be forward-looking statements. There are a number of important factors that could cause actual results or events to differ materially from those indicated by such forward-looking statements, including: limited operating history, need for future capital, risks inherent in the development and commercialization of potential products, protection of our intellectual property, and economic conditions generally. Additional information on potential factors that could affect our results and other risks and uncertainties are detailed from time to time in the companys periodic reports, including the report on Form 10-K for the year ended December 31, 2011. Forward-looking statements are based on the beliefs, opinions, and expectations of the companys management at the time they are made, and the company does not assume any obligation to update its forward-looking statements if those beliefs, opinions, expectations, or other circumstances should change. Forward-looking statements are based on the beliefs, opinions, and expectations of the companys management at the time they are made, and the company does not assume any obligation to update its forward-looking statements if those beliefs, opinions, expectations, or other circumstances should change. There can be no assurance that the Companys clinical trials will be successful.

Continue reading here:
ACT Issued Broad Patent for Human RPE Cells Derived From All Types of Pluripotent Stem Cells

26 July 2012 Last updated at 01:35 ET

Doctors say a County Monaghan teenager who made medical history by using his own stem cells to rebuild his throat is making a successful recovery.

Ciaran Finn-Lynch, 13, from Castleblayney, made medical history as the first child in the world to undergo the pioneering tracheal transplant.

He was born with a condition called Long Segment Tracheal Stenosis which meant he found it difficult to breathe.

Doctors say he has grown 11 centimetres in height and returned to school.

The surgery was a desperate attempt to save his life after earlier treatment failed.

Since the operation, Ciaran has been able to live a normal life free from medication to prevent his immune system rejecting the transplant.

He underwent the procedure at London's Great Ormond Street Hospital in March 2010.

It involved seeding stem cells taken from Ciaran's bone marrow into the collagen "skeleton" of a donor windpipe stripped of its own cells.

Once the structure was implanted, the stem cells were allowed to mature in his body, rather than the usual laboratory "bioreactor".

View original post here:
Boy's windpipe transplant success

The family immediately agreed and the operation took place at Great Ormond Street Hospital in March 2010.

Since then Ciaran, from County Down in Northern Ireland, has grown almost four-and-a-half inches (11cm) and he has returned to school. He has also been able to develop his musical interest as a drummer. A medical update is published in The Lancet today.

His family has declined to be interviewed, but at the time of the operation his mother Colleen said she and her husband Paul had got our boy back.

The procedure involved taking a windpipe from a 30-year-old Italian woman who had died and stripping it of living cells down to the inert collagen scaffold.

Four weeks later, Ciarans windpipe was removed. Sections of its lining were taken off and kept and the rest discarded. Bone marrow from Ciaran was harvested and the stem cells isolated.

The same day, the donor windpipe was inserted into Ciarans neck and his stem cells sprayed on to it.

Tiny sections of lining from his original windpipe were patched on to the replacement. These prompted the stem cells to turn into the right kind of tissue and kick-started growth of the windpipe lining.

Finally, the graft was injected with proteins to stimulate cell growth and differentiation, called cytokines.

The operation was the first attempt to grow stem cells in place in the body of a child, rather than growing an organ in a laboratory bioreactor.

It came only two years after the first windpipe replacement using stem cells in an adult, although in that case, carried out in Barcelona, the organ was grown in the lab.

Continued here:
Pioneering windpipe boy growing into healthy teenager

The first child in history to receive a trachea fashioned by his own stem cells has shown remarkable progress since the initial transplant two years ago, marking a new record for the novel procedure.

Ciaran Finn-Lynch, the now 13-year-old boy from the UK who the world's first child to receive the stem cell trachea transplant, is breathing normally and no longer needs anti-rejection medication, researchers reported in a paper published Wednesday in the journal Lancet.

The organ itself is strong, has not shown signs of rejection, and has even grown 11 centimeters since it had been transplanted, according to the researchers.

Ciaran was born with a rare condition known as Long Segment Tracheal Stenosis, marked by a small windpipe that does not grow and can restrict breathing. He underwent the stem cell transplant in March 2010 after a standard trachea transplant did not work.

Researchers at the Great Ormond Street Hospital for Children, the Karolinska Institute in Stockholm and the University College London, stripped cells from a donor trachea and then used Ciaran's own bone marrow stem cells to rebuild the airways in the body. They also infused growth proteins to generate the tissue lining.

Great Ormond Street Hospital Children's Charity

Using a patient's own stem cells not only could help to rebuild the fragile tissue, but also potentially could bypass the risk of having the organ rejected. A trachea is considered a difficult tissue to grow and transplant since it has a limited blood supply, according to Dr. Bill Putnam, professor and chair of the department of thoracic surgery at Vanderbilt University Medical Center, who was not involved in the research.

"I don't think there's anything standard about a tracheal transplant," said Putnam. "The fact that this single patient has survived for two years is worthy of notice."

Once the trachea was transplanted, the researchers continued to infuse growth proteins into the organ to continue stem cell generation. This technique allowed for researchers to transplant the organ faster instead of having to wait for the organ to grow outside of the body.

"Because the protocol used in this study was devised in an emergency, we applied empirically a new combination of technologies on the basis of previous clinical successes in non-airway settings," the researchers wrote, citing bioengineering techniques previously used to regenerate bone, nerves, and skin.

Excerpt from:
Stunning Recovery for First Child to Get Stem Cell Trachea

25 July 2012 Last updated at 21:04 ET By James Gallagher Health and science reporter, BBC News

The first child to have pioneering surgery to rebuild his windpipe with his own stem cells is doing well and is back in school.

Ciaran Finn-Lynch, who is now 13, had the ground-breaking surgery at London's Great Ormond Street Hospital in 2010.

Using Ciaran's own cells meant his immune system would not reject, and attack, the organ.

His surgeons said things were going well so far and that Ciaran could live the life of a normal teenager.

He was born with long-segment tracheal stenosis, which causes breathing difficulties. His lungs collapsed on the day he was born and he had major surgery to reconstruct his airways when he was six days old.

Metal tubes were used to hold his airways open, but in 2009 one caused huge amounts of bleeding when it damaged the main blood vessel coming out of the heart.

It was at this stage surgeons tried a pioneering operation. Instead of growing a new windpipe, they took a donor windpipe and stripped it of all the donor's cells. What was left was a three-dimensional web of collagen fibres which was transplanted into Ciaran.

Meanwhile, stem cells, which can become any other type of cell, from nerve to skin cells, were taken from Ciaran's bone marrow. These were then sprayed onto the newly transplanted windpipe.

The surgery had been tried once before in Spain, in 2008, on a 30-year-old woman, but Ciaran was the first child.

Read more here:
Stem-cell op child 'doing well'

MOBILE, Alabama -- Adult stem cells extracted during liposuction can be used to grow healthy new small-diameter blood vessels for use in heart bypass surgery and other procedures, new research shows.

The findings were presented today at the American Heart Association's Basic Cardiovascular Sciences 2012 Scientific Sessions in New Orleans.

The reason that's important, health officials said, is because millions of cardiovascular disease patients are in need of small-diameter vessel grafts for procedures requiring blood to be routed around blocked arteries.

These liposuction-derived vessels, grown in a lab, could help solve major problems associated with grafting blood vessels from elsewhere in the body or from using artificial blood vessels that are not living tissue, said Matthias Nollert, Ph.D., the lead author of the study, in a written statement.

Now, Nollert said, "small-diameter vessel grafts carry an inherent risk of clotting, being rejected or otherwise failing to function normally."

Nollert said the engineered blood vessels have good mechanical properties and "we believe they will contract normally when exposed to hormones. They also appear to prevent the accumulation of blood platelets -- a component in blood that causes arteries to narrow."

Here's how it works:

In the study, according to the American Heart Association, adult stem cells derived from fat are turned into smooth muscle cells in a laboratory, and then "seeded" onto a very thin collagen membrane.

As the stem cells multiplied, the researchers rolled them into tubes matching the diameter of small blood vessels. In three to four weeks, they grew into usable blood vessels.

Creating blood vessels with this technique has the potential for "off-the-shelf" replacement vessels that can be used in graft procedures, Nollert said.

More:
Stem cells from fat used to grow blood vessels in lab, research shows

In a Tissue-Engineering First, Doctors Think the Boy's New Windpipe Could Grow

July 25, 2012 -- Ciaran Finn-Lynch is an accidental medical pioneer. With his life in danger, doctors used the 13-year-old's own stem cells to grow him a new windpipe, and they did it inside his body -- a feat that's never been accomplished before.

"It's a really heroic story," says Harald C. Ott, MD, an instructor of medicine at Harvard Medical School in Boston. "They really saved this kid's life."

Ott worked out some of the science that made the procedure possible but was not directly involved in Ciaran's treatment.

Two years after the surgery, doctors say Ciaran (pronounced KEER-an) is living the life of a normal teen. He's grown more than 4 inches and gone back to school. Best of all, he has no need for an expensive and complicated regimen of anti-rejection drugs.

What doctors are learning from his case could help thousands of children born each year with life-threatening birth defects.

Ciaran was born with a windpipe so small and deformed that it caused his lungs to collapse.

Doctors managed to hold his airway open using metal tubes. But eventually the tubes eroded into his aorta, the large vessel that carries blood out of the heart. He was rushed to the hospital with massive bleeding. Twice.

The second time, the bleeding stopped on its own. That gave his doctors a small window of time to look for other options.

Two years earlier, scientists had devised a new way to create organs using a patient's own stem cells. Though the technique had only been tried in adults, they thought the same method might work for Ciaran.

Read more here:
Doctors Report Historic Transplant in Child